Cited by 471DNA Repair MechanismsBRCA gene mutations in cancerPARP inhibition in cancer therapy

RETRACTED ARTICLE: A mechanism for the suppression of homologous recombination in G1 cells

Open access
Orthwein, Alexandre, Noordermeer, Sylvie M., Wilson, Marcus D., Landry, Sébastien, Enchev, Radoslav I., Sherker, Alana, Munro, Meagan, Pinder, Jordan +5 more·2015·Nature

Abstract

DNA repair by homologous recombination is highly suppressed in G1 cells to ensure that mitotic recombination occurs solely between sister chromatids. Although many homologous recombination factors are cell-cycle regulated, the identity of the events that are both necessary and sufficient to suppress recombination in G1 cells is unknown. Here we report that the cell cycle controls the interaction of BRCA1 with PALB2-BRCA2 to constrain BRCA2 function to the S/G2 phases in human cells. We found that the BRCA1-interaction site on PALB2 is targeted by an E3 ubiquitin ligase composed of KEAP1, a PALB2-interacting protein, in complex with cullin-3 (CUL3)-RBX1 (ref. 6). PALB2 ubiquitylation suppresses its interaction with BRCA1 and is counteracted by the deubiquitylase USP11, which is itself under cell cycle control. Restoration of the BRCA1-PALB2 interaction combined with the activation of DNA-end resection is sufficient to induce homologous recombination in G1, as measured by RAD51 recruitment, unscheduled DNA synthesis and a CRISPR-Cas9-based gene-targeting assay. We conclude that the mechanism prohibiting homologous recombination in G1 minimally consists of the suppression of DNA-end resection coupled with a multi-step block of the recruitment of BRCA2 to DNA damage sites that involves the inhibition of BRCA1-PALB2-BRCA2 complex assembly. We speculate that the ability to induce homologous recombination in G1 cells with defined factors could spur the development of gene-targeting applications in non-dividing cells.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature16142This paper is marked retracted.

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Orthwein, A., Noordermeer, S. M., Wilson, M. D., Landry, S., Enchev, R. I., Sherker, A., Munro, M., Pinder, J., Salsman, J., Dellaire, G., Xia, B., Peter, M., & Durocher, D.
Affiliations
  • Mount Sinai Hospital (CA)
  • ETH Zurich (CH)
  • Dalhousie University (CA)
  • Rutgers, The State University of New Jersey (US)
Corresponding author
Durocher, Daniel
Venue
Nature
Published
2015-12-09
Volume
528
Issue
7582
Pages
422-426
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2202899490
Cited by
471
References
39
Citations by year
2026: 4 · 2025: 17 · 2024: 26 · 2023: 35 · 2022: 36 · 2021: 52 · 2020: 61 · 2019: 64 · 2018: 52 · 2017: 67 · 2016: 54 · 2015: 1
FWCI
25.17
Type
journal article
Language
en
Status
Retracted
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
Funders
  • Centers for Disease Control and Prevention
  • Canadian Institutes of Health Research (FDN143343 (, MOP84260)
  • National Cancer Institute (R01CA138804)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords
homologous recombination, G1 cell cycle, BRCA1, PALB2, BRCA2, DNA end resection, cell cycle regulation, Keap1, CUL3, RBX1, USP11, ubiquitination, sister chromatid recombination, DNA repair, CRISPR/Cas9
MeSH terms
Kelch-Like ECH-Associated Protein 1, Fanconi Anemia Complementation Group N Protein, Amino Acid Sequence, Carrier Proteins, Cell Line, DNA, DNA Damage, DNA Repair, Humans, Molecular Sequence Data, Nuclear Proteins, Protein Binding, Thiolester Hydrolases, G1 Phase, G2 Phase, S Phase, Gene Targeting, BRCA1 Protein, BRCA2 Protein, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Cullin Proteins, Multiprotein Complexes, Intracellular Signaling Peptides and Proteins, Rad51 Recombinase, Ubiquitination, Homologous Recombination, CRISPR-Cas Systems

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review